Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$157.28M+3.9%$151.39M+5.0%$144.17M+3.8%$138.91M+2.1%$136.03M+7.1%
$42.28M+5.7%$40.02M+8.7%$36.8M+3.3%$35.63M+4.8%$34.01M+6.7%
$199.56M+4.3%$191.41M+5.8%$180.97M+3.7%$174.54M+2.6%$170.04M+7.1%
-$199.56M-4.3%-$191.41M-5.8%-$180.97M-3.7%-$174.54M-2.6%-$170.04M-7.1%
-$176.01M-4.9%-$167.8M-6.7%-$157.24M-4.3%-$150.7M-3.2%-$146.09M-9.2%
-$1.67-1.8%-$1.64-3.8%-$1.58-1.9%-$1.550.0%-$1.55-6.9%
-$197.5M-4.3%-$189.37M-5.9%-$178.88M-3.7%-$172.45M-2.7%-$167.95M-7.1%
-$199.56M-4.3%-$191.41M-5.8%-$180.97M-3.7%-$174.54M-2.6%-$170.04M-7.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Edgewise Therapeutics, Inc.'s income statement data come from?
Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.